Novo Nordisk A/S (Novo Nordisk A/S) Change In Receivables : $0 Mil (TTM As of Mar. 2024)

View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk A/S Change In Receivables?

Novo Nordisk A/S's change in receivables for the quarter that ended in Mar. 2024 was $0 Mil. It means Novo Nordisk A/S's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Novo Nordisk A/S's change in receivables for the fiscal year that ended in Dec. 2023 was $-2,381 Mil. It means Novo Nordisk A/S's Accounts Receivable increased by $2,381 Mil from Dec. 2022 to Dec. 2023 .

Novo Nordisk A/S's Accounts Receivable for the quarter that ended in Mar. 2024 was $8,309 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Novo Nordisk A/S's Days Sales Outstanding for the three months ended in Mar. 2024 was 79.59.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Novo Nordisk A/S's liquidation value for the three months ended in Mar. 2024 was $-19,120 Mil.

Novo Nordisk A/S Change In Receivables Historical Data

The historical data trend for Novo Nordisk A/S's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Change In Receivables Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-493.24

-529.97

-2,094.67

-1,549.93

-2,380.90

Novo Nordisk A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Novo Nordisk A/S Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

Novo Nordisk A/S (NYSE:NVO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Novo Nordisk A/S's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	8309.134	/	9526.371	*	91
=	79.59

2. In Ben Graham's calculation of liquidation value, Novo Nordisk A/S's accounts receivable are only considered to be worth 75% of book value:

Novo Nordisk A/S's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1356.162	-	29156.827	+	0.75 * 8309.134	+	0.5 * 4898.102
=	-19,120

Novo Nordisk A/S Change In Receivables Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.